Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes

J B Kuemmerle-Deschner,S Morell-Dubois,J Hoyer,N Davis,S Jimenez,E Hachulla,N Patel,P N Hawkins,B Bader-Meunier,H J Lachmann,T A Tran,K S Leslie,R Cartwright,J Smith,A Gul,M Gattorno,A Widmer,R Preiss

doi:10.1136/ard.2011.152728

Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes

J B Kuemmerle-Deschner, S Morell-Dubois + Show 16 more

https://doi.org/10.1136/ard.2011.152728

Copy DOI

Journal: Annals of the Rheumatic Diseases	Publication Date: Aug 21, 2011
Citations: 196

Affiliation: Hôpital Claude Huriez, Universitätsklinikum Gießen und Marburg, Tris Pharma (United States), Hôpital Necker-Enfants Malades, Assistance Publique – Hôpitaux de Paris, Université Paris Cité, University College London, University of Wisconsin–Madison, Istituto Giannina Gaslini, Novartis (Switzerland)

#Cryopyrin-associated Periodic Syndrome #Efficacy Of Canakinumab In Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

ObjectiveLonger-term effects of prolonged selective interleukin-1β blockade with canakinumab were evaluated in the largest cohort of cryopyrin-associated periodic syndrome (CAPS) patients studied to date.MethodsAdult and paediatric CAPS patients (n=166, including...

Full Text